Innovative drugs are expected to break the treatment dilemma of patients with acute lymphocyte leukemia

Acute lymphocyte leukemia (ALL) is one of the four main types of leukemia. It is a malignant tumor disease that is abnormally proliferated in the bone marrow that originated from lymphocytes.

At present, the treatment of patients in domestic ALL is mainly chemotherapy. Under the traditional standard chemotherapy plan, the treatment of patients with R/R ALL is difficult to achieve a complete relief (CR) and obtain long -term survival. According to data statistics, 40%-50%of adult patients will eventually experience recurrence. The current treatment plan CR rate of recurrence or cure ALL patients is lower, and the survival rate is not good. After the recurrence of adult ALL patients, the overall CR rate of the past treatment plan is about 40%, the 3 -year survival rate is about 11%, and the total survival rate of patients in five years is less than 10%.

Although after many years of exploration and improvement, adult R/R B-ALL still exists in many unsatisfactory clinical needs. For example, traditional treatment plans have not significantly improved long-term survival of patients with recurrence. Long -term sequelae, affecting the quality of life. Fortunately, a few days ago, the injection of acute leukemia innovation drugs was opened in the country's first batch of prescriptions in the country. Among them, Beijing's first prescription was issued by Huang Xiaojun, the Institute of Hematology of Peking University. The antibody coupling drug (ADC) of the recurrence or cure forehead B cell ALL (R/R B-ALL) officially begins to benefit the patient, which is expected to break the treatment difficulties and provide a new choice for the anticipated Chinese leukemia patients who are looking forward to. , Bring new hope to more families.

Huang Xiaojun, director of the Institute of Hematology of Peking University, said that the arrival of the drug can give patients more treatment options. More patients with leukemia will have the opportunity to transplant hematopoietic stem cells in the future, and thus achieve the purpose of long -term survival. It is also expected to suffer more innovative drugs to be included in the medical insurance directory in the future to reduce the economic burden of patients. (Guangming Daily All Media Reporter Tian Yating)

The picture shows the team of Huang Xiaojun, the Institute of Hematology of Peking University

- END -